| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00210-009-0487-8 |
| P698 | PubMed publication ID | 20082192 |
| P2093 | author name string | Ursula Ravens | |
| P2860 | cites work | Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein | Q24642787 |
| Ablation of a Ca2+-activated K+ channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation | Q28118782 | ||
| Potassium leak channels and the KCNK family of two-P-domain subunits | Q28205333 | ||
| Cardiac excitation-contraction coupling | Q28216347 | ||
| Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation | Q28245803 | ||
| Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density | Q28284487 | ||
| Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 | ||
| Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation | Q30476498 | ||
| Cardiac adrenergic control and atrial fibrillation | Q33792556 | ||
| Ventricular fibrillation: mechanisms of initiation and maintenance | Q33938669 | ||
| Biological pacemaker created by gene transfer | Q34149202 | ||
| A comparison of rate control and rhythm control in patients with atrial fibrillation | Q34162727 | ||
| Molecular identification and functional roles of a Ca(2+)-activated K+ channel in human and mouse hearts | Q34247000 | ||
| The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation | Q34473254 | ||
| New ideas about atrial fibrillation 50 years on. | Q34503407 | ||
| hERG potassium channels and cardiac arrhythmia | Q34504394 | ||
| Dronedarone | Q34610881 | ||
| Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current | Q34693729 | ||
| Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats | Q34721297 | ||
| Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression | Q34997952 | ||
| Remodeling of cardiomyocyte ion channels in human atrial fibrillation | Q35186203 | ||
| Electrophysiological changes in heart failure and their relationship to arrhythmogenesis | Q35635094 | ||
| Nonchannel drug targets in atrial fibrillation | Q35729433 | ||
| Activators of cation channels: potential in treatment of channelopathies | Q35988564 | ||
| Early electrical remodeling in rabbit pulmonary vein results from trafficking of intracellular SK2 channels to membrane sites | Q36082827 | ||
| Epidemiological profile of atrial fibrillation: a contemporary perspective | Q36272311 | ||
| Calcium-activated potassium channels and the regulation of vascular tone | Q36380601 | ||
| Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. | Q36427756 | ||
| Calcium-activated nonselective cation channels in mammalian cardiomyocytes | Q36596071 | ||
| Cardiac fibrillation: from ion channels to rotors in the human heart | Q36793599 | ||
| Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation | Q36842497 | ||
| Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches | Q37178627 | ||
| Roles of TRP channels in the development of cardiac hypertrophy | Q37207026 | ||
| Role of potassium currents in cardiac arrhythmias | Q37226299 | ||
| New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value | Q37231704 | ||
| Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. | Q37268790 | ||
| The pathological role of transient receptor potential channels in heart disease | Q37388339 | ||
| Transient receptor potential: a large family of new channels of which several are involved in cardiac arrhythmia | Q37398665 | ||
| Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation | Q37584282 | ||
| Atrial remodeling and atrial fibrillation: mechanisms and implications. | Q37609710 | ||
| Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance | Q37638445 | ||
| Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides | Q37639916 | ||
| The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. | Q38756624 | ||
| Synthesis and characterisation of NS13558: a new important tool for addressing KCa1.1 channel function ex vivo | Q39792452 | ||
| Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation | Q42459986 | ||
| Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK,ACh channels in patients with chronic atrial fibrillation | Q42509641 | ||
| Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine | Q43196284 | ||
| Vernakalant hydrochloride for the treatment of atrial fibrillation | Q43235607 | ||
| Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target | Q43270475 | ||
| The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. | Q43272225 | ||
| Late sodium current is a novel target for amiodarone: studies in failing human myocardium | Q43601320 | ||
| Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane | Q44201844 | ||
| Functional characterization of a Ca(2+)-activated non-selective cation channel in human atrial cardiomyocytes | Q44879643 | ||
| Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. | Q45284438 | ||
| The anti-arrhythmic peptide AAP10 remodels Cx43 and Cx40 expression and function | Q46072269 | ||
| Defective cardiac ryanodine receptor regulation during atrial fibrillation | Q46455370 | ||
| Mechanical deformation of ventricular myocytes modulates both TRPC6 and Kir2.3 channels | Q46477997 | ||
| Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings | Q46522726 | ||
| Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? | Q47572890 | ||
| The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. | Q48797106 | ||
| Signal-averaged P wave: predictor of atrial fibrillation | Q49088971 | ||
| Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation? | Q51328980 | ||
| Calcium-activated potassium current: a novel ion channel candidate in atrial fibrillation. | Q51742032 | ||
| Sudden cardiac death in heart failure. The role of abnormal repolarization | Q72791800 | ||
| Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells | Q73298210 | ||
| Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity | Q73645093 | ||
| Tarantula peptide inhibits atrial fibrillation | Q73851329 | ||
| Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat | Q73914865 | ||
| Autonomic tone variations before the onset of paroxysmal atrial fibrillation | Q74268938 | ||
| Characterization of a [Ca2+]i-dependent current in human atrial and ventricular cardiomyocytes in the absence of Na+ and K+ | Q77746025 | ||
| Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort | Q77960625 | ||
| Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs | Q79562278 | ||
| Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias | Q83058608 | ||
| [Autonomously promoted extension effect in Purkinje fibers, papillary muscles and trabeculae carneae of rhesus monkeys] | Q93766447 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 187-193 | |
| P577 | publication date | 2010-01-15 | |
| P1433 | published in | Naunyn-Schmiedeberg's Archives of Pharmacology | Q1468251 |
| P1476 | title | Novel pharmacological approaches for antiarrhythmic therapy | |
| P478 | volume | 381 |
| Q35089887 | Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels |
| Q37847174 | Emerging antiarrhythmic agents: a personal view from the Far East |
| Q42160738 | In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics |
| Q34953291 | Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation |
| Q48644420 | Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels. |
| Q45872055 | Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study |
| Q34772923 | The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation |
Search more.